CJC-1295

CJC-1295 (No DAC) is a synthetic analog of growth hormone–releasing hormone (GHRH) developed by ConjuChem Biotechnologies. Unlike CJC-1295 with DAC, this version does not contain the Drug Affinity Complex (DAC), meaning it does not bind to albumin and therefore has a shorter half-life of ~30 minutes to 2 hours.

Despite its shorter duration, CJC-1295 (No DAC) effectively stimulates the anterior pituitary to release growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in a dose-dependent manner. Its activity leads to transient but robust increases in GH and IGF-1 lasting 6–8 hours post-injection.

Key distinction: Unlike direct GH administration, CJC-1295 (No DAC) preserves physiologic pulsatile GH release while amplifying natural baseline levels.

Sustained GH Elevation: 2–10 fold increase for 6–8 hours.
IGF-1 Elevation: 1.5–3 fold increase in parallel with GH rise.
Cumulative Effects: repeat dosing supports baseline hormonal upregulation.
Improved Growth & Body Composition: normalizes growth in GH-deficient states.
Muscle Development: enhanced protein synthesis via IGF-1 pathways.
Fat Metabolism: increased lipolysis and potential prolactin normalization.
Recovery Support: collagen synthesis, tissue remodeling, accelerated repair.
Sleep Optimization: improved slow-wave and REM cycles.
Pituitary Health: promotes somatotroph proliferation and GH expression.
Metabolic Optimization: favorable changes in serum protein profiles.

Teichman SL, et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295, a long-acting GHRH analog, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536
Alba M, et al. Once-daily CJC-1295, a long-acting GHRH analog, normalizes growth in GHRH knockout mice. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
Ionescu M, Frohman LA. Pulsatile GH secretion persists during continuous CJC-1295 stimulation. J Clin Endocrinol Metab. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702
Sackmann-Sala L, et al. Activation of the GH/IGF-1 axis by CJC-1295 results in serum protein profile changes. Growth Horm IGF Res. 2009;19(6):471-477. doi:10.1016/j.ghir.2009.03.001
Jetté L, et al. Identification of CJC-1295 as a long-lasting GRF analog via pituitary activation. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286

$75.00

Per Unit

In stock